CapitalOne initiated coverage on Biomea Fusion with a new price target
$BMEA
Biotechnology: Pharmaceutical Preparations
Health Care
CapitalOne initiated coverage of Biomea Fusion with a rating of Overweight and set a new price target of $25.00
Get the next $BMEA alert in real time by email
Get the next $BMEA alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $BMEA
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/9/2024 | $128.00 | Buy | Edward Jones |
| 9/27/2024 | $18.00 | Neutral → Buy | Rodman & Renshaw |
| 9/27/2024 | $54.00 | Hold → Buy | Truist |
| 8/29/2024 | $25.00 | Overweight | CapitalOne |
| 6/11/2024 | Buy → Hold | Truist | |
| 6/7/2024 | $30.00 → $5.00 | Overweight → Equal Weight | Barclays |
| 4/2/2024 | $51.00 → $14.00 | Overweight → Neutral | JP Morgan |
| 2/6/2024 | $55.00 | Buy | Truist |
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
Mick Hitchcock, Ph.D., appointed Interim Chief Executive OfficerBiomea preparing icovamenib for late-stage clinical developmentMultiple milestones anticipated in 2025 including:FDA meeting anticipated in first half 2025 to discuss icovamenib late-stage development in severe insulin deficient patientsCOVALENT-111 (T2D) 52-week data anticipated in second half 2025COVALENT-112 (T1D) open label data anticipated in second half 2025BMF-650 IND application submission planned in second half 2025 REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, reported
Biomea Fusion Announces Leadership Transition
Board member Mick Hitchcock, named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann continuing at Biomea in current role. REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea," or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, announced today an executive leadership change to help ensure the company realizes its full potential developing a novel therapy for diabetes. Specifically, Mick Hitchcock, a current board member since 2021, will succeed Thomas Butler as interim Chief Executive Officer. The change is effective immediately. "As a long-time member of Biomea's Board, I've had the privilege
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose
Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of icovamenib Strong correlation between C-peptide increase and HbA1c reduction (r = -0.73, p<0.0001) across all dosing groups (n=23) support the proposed mechanism of beta cell restorationBest response observed in prespecified, beta-cell deficient patients on one or more antihyperglycemic agents at baseline, achieving a statistically significant placebo-adjusted mean reduction in HbA1c of 1.47% at Week 26 (p=0.022), after only 12 weeks of 100 mg once daily icovamenibPreclinical in vivo experiments indicat
Edward Jones initiated coverage on Biomea Fusion with a new price target
Edward Jones initiated coverage of Biomea Fusion with a rating of Buy and set a new price target of $128.00
Biomea Fusion upgraded by Rodman & Renshaw with a new price target
Rodman & Renshaw upgraded Biomea Fusion from Neutral to Buy and set a new price target of $18.00
Biomea Fusion upgraded by Truist with a new price target
Truist upgraded Biomea Fusion from Hold to Buy and set a new price target of $54.00
Director Hitchcock Michael J.M. bought $100,600 worth of shares (10,000 units at $10.06), increasing direct ownership by 200% to 15,000 units (SEC Form 4)
4 - Biomea Fusion, Inc. (0001840439) (Issuer)
Chief Financial Officer Valle Franco was granted 4,448 shares and bought $55,361 worth of shares (12,509 units at $4.43), increasing direct ownership by 66% to 42,500 units (SEC Form 4)
4 - Biomea Fusion, Inc. (0001840439) (Issuer)
SEC Form 4 filed by Interim CEO Hitchcock Michael J.M.
4 - Biomea Fusion, Inc. (0001840439) (Issuer)
Chief Financial Officer Valle Franco was granted 495 shares, increasing direct ownership by 1% to 42,995 units (SEC Form 4)
4 - Biomea Fusion, Inc. (0001840439) (Issuer)
Director Hitchcock Michael J.M. bought $100,600 worth of shares (10,000 units at $10.06), increasing direct ownership by 200% to 15,000 units (SEC Form 4)
4 - Biomea Fusion, Inc. (0001840439) (Issuer)
SEC Form 10-K filed by Biomea Fusion Inc.
10-K - Biomea Fusion, Inc. (0001840439) (Filer)
Biomea Fusion Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Biomea Fusion, Inc. (0001840439) (Filer)
Biomea Fusion Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure
8-K - Biomea Fusion, Inc. (0001840439) (Filer)
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
Mick Hitchcock, Ph.D., appointed Interim Chief Executive OfficerBiomea preparing icovamenib for late-stage clinical developmentMultiple milestones anticipated in 2025 including:FDA meeting anticipated in first half 2025 to discuss icovamenib late-stage development in severe insulin deficient patientsCOVALENT-111 (T2D) 52-week data anticipated in second half 2025COVALENT-112 (T1D) open label data anticipated in second half 2025BMF-650 IND application submission planned in second half 2025 REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, reported
Biomea Fusion Announces Leadership Transition
Board member Mick Hitchcock, named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann continuing at Biomea in current role. REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea," or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, announced today an executive leadership change to help ensure the company realizes its full potential developing a novel therapy for diabetes. Specifically, Mick Hitchcock, a current board member since 2021, will succeed Thomas Butler as interim Chief Executive Officer. The change is effective immediately. "As a long-time member of Biomea's Board, I've had the privilege
Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
Demonstrated durable HbA1c lowering in the escalation portion of ongoing Phase II study in type 2 diabetes (COVALENT-111), with 84% of all patients showing a reduction of HbA1c after 4 weeks dosing and 74% after another 8 weeks off-treatment periodExpansion portion of COVALENT-111 cleared and actively enrolling in the U.S. and Canada; expected to enroll approximately 200 adults with type 2 diabetesInvestigational new drug (IND) application cleared for Phase II clinical trial of BMF-219 in type 1 diabetes (COVALENT-112); enrollment of 150 adults with type 1 diabetes anticipated to begin in Q4 2023Dosed first relapsed/refractory AML patient with BMF-500, Biomea's novel third generation investi
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient populationBest response achieved in target, beta-cell deficient patients on one or more antidiabetic agents at baseline, showing a placebo-adjusted mean reduction of 1.47% in HbA1c at Week 26 with statistical significance, after only 12 weeks of dosing icovamenib with 100 mgIcovamenib was well-tolerated, with no adverse-event related discontinuations, no hypoglycemic events and no serious adverse events REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Tuesday, December 17, 2024 at 8:00 am EST to present topline results from COVALENT-111, the company's Phase II trial of icovamenib in patients with type 2 diabetes. Conference Call and Webcast Details Webcast of Biomea's investor update on Tuesday, December 17, 2024, at 8:00 am EST will be available to reg
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
Preliminary data supports BMF-500's potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemiaBMF-500 showed a favorable safety and tolerability profile, with no dose-limiting toxicities observed across all dose levelsPharmacokinetic and pharmacodynamic data confirmed on-target FMS-like tyrosine kinase 3 (FLT3) inhibition, demonstrating dose-proportional activity and good compartmental penetrationPreliminary Phase I data for BMF-500 in R/R acute leukemia patients with FLT3 gene mutations having failed gilteritinib indicated clinical activity with evidence of responses, including a first complete response with incomplete hematologic recove
Amendment: SEC Form SC 13G/A filed by Biomea Fusion Inc.
SC 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)
Amendment: SEC Form SC 13G/A filed by Biomea Fusion Inc.
SC 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)
SEC Form SC 13G filed by Biomea Fusion Inc.
SC 13G - Biomea Fusion, Inc. (0001840439) (Subject)